1
|
Lőrincz EB, Herczeg M, Houser J, Rievajová M, Kuki Á, Malinovská L, Naesens L, Wimmerová M, Borbás A, Herczegh P, Bereczki I. Amphiphilic Sialic Acid Derivatives as Potential Dual-Specific Inhibitors of Influenza Hemagglutinin and Neuraminidase. Int J Mol Sci 2023; 24:17268. [PMID: 38139095 PMCID: PMC10743929 DOI: 10.3390/ijms242417268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/01/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023] Open
Abstract
In the shadow of SARS-CoV-2, influenza seems to be an innocent virus, although new zoonotic influenza viruses evolved by mutations may lead to severe pandemics. According to WHO, there is an urgent need for better antiviral drugs. Blocking viral hemagglutinin with multivalent N-acetylneuraminic acid derivatives is a promising approach to prevent influenza infection. Moreover, dual inhibition of both hemagglutinin and neuraminidase may result in a more powerful effect. Since both viral glycoproteins can bind to neuraminic acid, we have prepared three series of amphiphilic self-assembling 2-thio-neuraminic acid derivatives constituting aggregates in aqueous medium to take advantage of their multivalent effect. One of the series was prepared by the azide-alkyne click reaction, and the other two by the thio-click reaction to yield neuraminic acid derivatives containing lipophilic tails of different sizes and an enzymatically stable thioglycosidic bond. Two of the three bis-octyl derivatives produced proved to be active against influenza viruses, while all three octyl derivatives bound to hemagglutinin and neuraminidase from H1N1 and H3N2 influenza types.
Collapse
Affiliation(s)
- Eszter Boglárka Lőrincz
- Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary; (E.B.L.); (M.H.); (A.B.); (P.H.)
- Doctoral School of Pharmaceutical Sciences, University of Debrecen, H-4032 Debrecen, Hungary
| | - Mihály Herczeg
- Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary; (E.B.L.); (M.H.); (A.B.); (P.H.)
| | - Josef Houser
- National Centre for Biomolecular Research, Masaryk University, 611 37 Brno, Czech Republic; (J.H.); (L.M.); (M.W.)
- Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic
| | - Martina Rievajová
- Department of Biochemistry, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic;
| | - Ákos Kuki
- Department of Applied Chemistry, University of Debrecen, H-4032 Debrecen, Hungary;
| | - Lenka Malinovská
- National Centre for Biomolecular Research, Masaryk University, 611 37 Brno, Czech Republic; (J.H.); (L.M.); (M.W.)
- Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic
| | - Lieve Naesens
- Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium;
| | - Michaela Wimmerová
- National Centre for Biomolecular Research, Masaryk University, 611 37 Brno, Czech Republic; (J.H.); (L.M.); (M.W.)
- Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic
- Department of Biochemistry, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic;
| | - Anikó Borbás
- Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary; (E.B.L.); (M.H.); (A.B.); (P.H.)
- National Laboratory of Virology, University of Pécs, H-7624 Pécs, Hungary
- HUN-REN–UD Molecular Recognition and Interaction Research Group, University of Debrecen, H-4032 Debrecen, Hungary
| | - Pál Herczegh
- Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary; (E.B.L.); (M.H.); (A.B.); (P.H.)
| | - Ilona Bereczki
- Department of Pharmaceutical Chemistry, University of Debrecen, H-4032 Debrecen, Hungary; (E.B.L.); (M.H.); (A.B.); (P.H.)
- National Laboratory of Virology, University of Pécs, H-7624 Pécs, Hungary
| |
Collapse
|
2
|
Zhong F, Zhang Q, Chen K, Lan S, Yang W, Gan X. Eco-Friendly Cinnamic Acid Derivatives Containing Glycoside Scaffolds as Potential Antiviral Agents. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2023; 71:17752-17762. [PMID: 37943715 DOI: 10.1021/acs.jafc.3c06318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2023]
Abstract
Natural products are a crucial source in the development of new eco-friendly antiviral agents to control plant viral diseases. In our previous studies, some ferulic acid derivatives with good antiviral activity were obtained as an immune activator. To continue the discovery of eco-friendly antiviral agents, different monosaccharides were introduced into cinnamic acid skeletons by an activity-based strategy to obtain a series of cinnamic acid derivatives containing glycoside scaffolds, and their antiviral activities against tobacco mosaic virus (TMV) and tomato spotted wilt virus (TSWV) were evaluated. Among them, compound 8d showed the greatest protective activities against TMV and TSWV, with the EC50 values of 128.5 and 236.8 μg mL-1, respectively, which were superior to those of ningnanmycin (238.5 and 315.7 μg mL-1, respectively). Moreover, compound 8d could significantly improve the defense enzyme activities of peroxidase, chitinase, and β-1,3-glucanase. Proteomic and transcriptome analyses indicated that compound 8d regulated gene transcription and protein expression levels involved in the defense response to resist virus infection. The present study revealed that compound 8d is a potential lead candidate for the development of novel, eco-friendly, and natural-product-based antiviral agents.
Collapse
Affiliation(s)
- Fangping Zhong
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, Guizhou 550025, People's Republic of China
| | - Qi Zhang
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, Guizhou 550025, People's Republic of China
| | - Kejia Chen
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, Guizhou 550025, People's Republic of China
| | - Shichao Lan
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, Guizhou 550025, People's Republic of China
| | - Wenchao Yang
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, Guizhou 550025, People's Republic of China
| | - Xiuhai Gan
- National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Guizhou University, Guiyang, Guizhou 550025, People's Republic of China
| |
Collapse
|
3
|
Yang X, Sun H, Zhang Z, Ou W, Xu F, Luo L, Liu Y, Chen W, Chen J. Antiviral Effect of Ginsenosides rk1 against Influenza a Virus Infection by Targeting the Hemagglutinin 1-Mediated Virus Attachment. Int J Mol Sci 2023; 24:ijms24054967. [PMID: 36902398 PMCID: PMC10003360 DOI: 10.3390/ijms24054967] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 02/28/2023] [Accepted: 03/02/2023] [Indexed: 03/08/2023] Open
Abstract
Influenza A virus (IAV) infections have been a serious hazard to public health everywhere. With the growing concern of drug-resistant IAV strains, there is an urgent need for novel anti-IAV medications, especially those with alternative mechanisms of action. Hemagglutinin (HA), an IAV glycoprotein, plays critical roles in the early stage of virus infection, including receptor binding and membrane fusion, making it a good target for developing anti-IAV drugs. Panax ginseng is a widely used herb in traditional medicine with extensive biological effects in various disease models, and its extract was reported to show protection in IAV-infected mice. However, the main effective anti-IAV constituents in panax ginseng remain unclear. Here, we report that ginsenoside rk1 (G-rk1) and G-rg5, out of the 23 screened ginsenosides, exhibit significant antiviral effects against 3 different IAV subtypes (H1N1, H5N1, and H3N2) in vitro. Mechanistically, G-rk1 blocked IAV binding to sialic acid in a hemagglutination inhibition (HAI) assay and an indirect ELISA assay; more importantly, we showed that G-rk1 interacted with HA1 in a dose-dependent manner in a surface plasmon resonance (SPR) analysis. Furthermore, G-rk1 treatment by intranasal inoculation effectively reduced the weight loss and mortality of mice challenged with a lethal dose of influenza virus A/Puerto Rico/8/34 (PR8). In conclusion, our findings reveal for the first time that G-rk1 possesses potent anti-IAV effects in vitro and in vivo. We have also identified and characterized with a direct binding assay a novel ginseng-derived IAV HA1 inhibitor for the first time, which could present potential approaches to prevent and treat IAV infections.
Collapse
Affiliation(s)
- Xia Yang
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Hailiang Sun
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Zhening Zhang
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Weixin Ou
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Fengxiang Xu
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Ling Luo
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Yahong Liu
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
| | - Weisan Chen
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC 3086, Australia
- Correspondence: (W.C.); (J.C.); Tel./Fax: +61-3-9479-3961 (W.C.); +86-20-8528-0234 (J.C.)
| | - Jianxin Chen
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou 510642, China
- College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Correspondence: (W.C.); (J.C.); Tel./Fax: +61-3-9479-3961 (W.C.); +86-20-8528-0234 (J.C.)
| |
Collapse
|
4
|
Self-association of the glycopeptide antibiotic teicoplanin A2 in aqueous solution studied by molecular hydrodynamics. Sci Rep 2023; 13:1969. [PMID: 36737502 PMCID: PMC9895975 DOI: 10.1038/s41598-023-28740-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 01/24/2023] [Indexed: 02/05/2023] Open
Abstract
The natural glycopeptide antibiotic teicoplanin is used for the treatment of serious Gram-positive related bacterial infections and can be administered intravenously, intramuscularly, topically (ocular infections), or orally. It has also been considered for targeting viral infection by SARS-CoV-2. The hydrodynamic properties of teicoplanin A2 (M1 = 1880 g/mol) were examined in phosphate chloride buffer (pH 6.8, I = 0.10 M) using sedimentation velocity and sedimentation equilibrium in the analytical ultracentrifuge together with capillary (rolling ball) viscometry. In the concentration range, 0-10 mg/mL teicoplanin A2 was found to self-associate plateauing > 1 mg/mL to give a molar mass of (35,400 ± 1000) g/mol corresponding to ~ (19 ± 1) mers, with a sedimentation coefficient s20, w = ~ 4.65 S. The intrinsic viscosity [[Formula: see text]] was found to be (3.2 ± 0.1) mL/g: both this, the value for s20,w and the hydrodynamic radius from dynamic light scattering are consistent with a globular macromolecular assembly, with a swelling ratio through dynamic hydration processes of ~ 2.
Collapse
|
5
|
Ma L, Li Y, Shi T, Zhu Z, Zhao J, Xie Y, Wen J, Guo S, Wang J, Ding J, Liang C, Shan G, Li Q, Ge M, Cen S. Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors. Biomed Pharmacother 2023; 158:114213. [PMID: 36916436 PMCID: PMC9808420 DOI: 10.1016/j.biopha.2023.114213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 12/23/2022] [Accepted: 01/02/2023] [Indexed: 01/04/2023] Open
Abstract
The rapid emergence of highly transmissible SARS-CoV-2 variants poses serious threat to the efficacy of vaccines and neutralizing antibodies. Thus, there is an urgent need to develop new and effective inhibitors against SARS-CoV-2 and future outbreaks. Here, we have identified a series of glycopeptide antibiotics teicoplanin derivatives that bind to the SARS-CoV-2 spike (S) protein, interrupt its interaction with ACE2 receptor and selectively inhibit viral entry mediated by S protein. Computation modeling predicts that these compounds interact with the residues in the receptor binding domain. More importantly, these teicoplanin derivatives inhibit the entry of both pseudotyped SARS-CoV-2 Delta and Omicron variants. Our study demonstrates the feasibility of developing small molecule entry inhibitors by targeting the interaction of viral S protein and ACE2. Together, considering the proven safety and pharmacokinetics of teicoplanin as a glycopeptide antibiotic, the teicoplanin derivatives hold great promise of being repurposed as pan-SARS-CoV-2 inhibitors.
Collapse
Affiliation(s)
- Ling Ma
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Yali Li
- Shanghai Laiyi Center for Biopharmaceutical R&D, Shanghai, China
| | - Ting Shi
- State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
| | - Zhiling Zhu
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Jianyuan Zhao
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Yongli Xie
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Jiajia Wen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Saisai Guo
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Jing Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Jiwei Ding
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Chen Liang
- Lady Davis Institute for Medical Research and McGill AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
| | - Guangzhi Shan
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China
| | - Quanjie Li
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
| | - Mei Ge
- Shanghai Laiyi Center for Biopharmaceutical R&D, Shanghai, China.
| | - Shan Cen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China; CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
| |
Collapse
|
6
|
Gribble GW. Naturally Occurring Organohalogen Compounds-A Comprehensive Review. PROGRESS IN THE CHEMISTRY OF ORGANIC NATURAL PRODUCTS 2023; 121:1-546. [PMID: 37488466 DOI: 10.1007/978-3-031-26629-4_1] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/26/2023]
Abstract
The present volume is the third in a trilogy that documents naturally occurring organohalogen compounds, bringing the total number-from fewer than 25 in 1968-to approximately 8000 compounds to date. Nearly all of these natural products contain chlorine or bromine, with a few containing iodine and, fewer still, fluorine. Produced by ubiquitous marine (algae, sponges, corals, bryozoa, nudibranchs, fungi, bacteria) and terrestrial organisms (plants, fungi, bacteria, insects, higher animals) and universal abiotic processes (volcanos, forest fires, geothermal events), organohalogens pervade the global ecosystem. Newly identified extraterrestrial sources are also documented. In addition to chemical structures, biological activity, biohalogenation, biodegradation, natural function, and future outlook are presented.
Collapse
Affiliation(s)
- Gordon W Gribble
- Department of Chemistry, Dartmouth College, Hanover, NH, 03755, USA.
| |
Collapse
|
7
|
Bereczki I, Vimberg V, Lőrincz E, Papp H, Nagy L, Kéki S, Batta G, Mitrović A, Kos J, Zsigmond Á, Hajdú I, Lőrincz Z, Bajusz D, Petri L, Hodek J, Jakab F, Keserű GM, Weber J, Naesens L, Herczegh P, Borbás A. Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria. Sci Rep 2022; 12:16001. [PMID: 36163239 PMCID: PMC9511441 DOI: 10.1038/s41598-022-20182-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 09/08/2022] [Indexed: 11/09/2022] Open
Abstract
Patients infected with SARS-CoV-2 risk co-infection with Gram-positive bacteria, which severely affects their prognosis. Antimicrobial drugs with dual antiviral and antibacterial activity would be very useful in this setting. Although glycopeptide antibiotics are well-known as strong antibacterial drugs, some of them are also active against RNA viruses like SARS-CoV-2. It has been shown that the antiviral and antibacterial efficacy can be enhanced by synthetic modifications. We here report the synthesis and biological evaluation of seven derivatives of teicoplanin bearing hydrophobic or superbasic side chain. All but one teicoplanin derivatives were effective in inhibiting SARS-CoV-2 replication in VeroE6 cells. One lipophilic and three perfluoroalkyl conjugates showed activity against SARS-CoV-2 in human Calu-3 cells and against HCoV-229E, an endemic human coronavirus, in HEL cells. Pseudovirus entry and enzyme inhibition assays established that the teicoplanin derivatives efficiently prevent the cathepsin-mediated endosomal entry of SARS-CoV-2, with some compounds inhibiting also the TMPRSS2-mediated surface entry route. The teicoplanin derivatives showed good to excellent activity against Gram-positive bacteria resistant to all approved glycopeptide antibiotics, due to their ability to dually bind to the bacterial membrane and cell-wall. To conclude, we identified three perfluoralkyl and one monoguanidine analog of teicoplanin as dual inhibitors of Gram-positive bacteria and SARS-CoV-2.
Collapse
Affiliation(s)
- Ilona Bereczki
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary.,National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary
| | - Vladimir Vimberg
- Laboratory for Biology of Secondary Metabolism, Institute of Microbiology, Academy of Sciences of the Czech Republic, BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic
| | - Eszter Lőrincz
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary.,Institute of Healthcare Industry, University of Debrecen, Debrecen, Nagyerdei körút 98, 4032, Hungary.,Doctoral School of Pharmaceutical Sciences, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary
| | - Henrietta Papp
- National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary.,Faculty of Sciences, Institute of Biology, University of Pécs, Pecs, Ifjúság útja 6, 7624, Hungary
| | - Lajos Nagy
- Department of Applied Chemistry, University of Debrecen, Debrecen, 4032, Hungary
| | - Sándor Kéki
- Department of Applied Chemistry, University of Debrecen, Debrecen, 4032, Hungary
| | - Gyula Batta
- Department of Organic Chemistry, University of Debrecen, Debrecen, 4032, Hungary
| | - Ana Mitrović
- Department of Biotechnology, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia
| | - Janko Kos
- Department of Biotechnology, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia.,Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia
| | - Áron Zsigmond
- TargetEx Ltd., Dunakeszi, Madách Imre utca 31/2, 2120, Hungary
| | - István Hajdú
- TargetEx Ltd., Dunakeszi, Madách Imre utca 31/2, 2120, Hungary
| | - Zsolt Lőrincz
- TargetEx Ltd., Dunakeszi, Madách Imre utca 31/2, 2120, Hungary
| | - Dávid Bajusz
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Magyar tudósok krt. 2, 1117, Hungary
| | - László Petri
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Magyar tudósok krt. 2, 1117, Hungary
| | - Jan Hodek
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nam. 2, 16000, Prague 6, Czech Republic
| | - Ferenc Jakab
- National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary.,Faculty of Sciences, Institute of Biology, University of Pécs, Pecs, Ifjúság útja 6, 7624, Hungary
| | - György M Keserű
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Magyar tudósok krt. 2, 1117, Hungary.
| | - Jan Weber
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nam. 2, 16000, Prague 6, Czech Republic
| | - Lieve Naesens
- Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium.
| | - Pál Herczegh
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary
| | - Anikó Borbás
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary. .,National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary.
| |
Collapse
|
8
|
van Groesen E, Innocenti P, Martin NI. Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022. ACS Infect Dis 2022; 8:1381-1407. [PMID: 35895325 PMCID: PMC9379927 DOI: 10.1021/acsinfecdis.2c00253] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The accelerated appearance of drug-resistant bacteria poses an ever-growing threat to modern medicine's capacity to fight infectious diseases. Gram-positive species such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae continue to contribute significantly to the global burden of antimicrobial resistance. For decades, the treatment of serious Gram-positive infections relied upon the glycopeptide family of antibiotics, typified by vancomycin, as a last line of defense. With the emergence of vancomycin resistance, the semisynthetic glycopeptides telavancin, dalbavancin, and oritavancin were developed. The clinical use of these compounds is somewhat limited due to toxicity concerns and their unusual pharmacokinetics, highlighting the importance of developing next-generation semisynthetic glycopeptides with enhanced antibacterial activities and improved safety profiles. This Review provides an updated overview of recent advancements made in the development of novel semisynthetic glycopeptides, spanning the period from 2014 to today. A wide range of approaches are covered, encompassing innovative strategies that have delivered semisynthetic glycopeptides with potent activities against Gram-positive bacteria, including drug-resistant strains. We also address recent efforts aimed at developing targeted therapies and advances made in extending the activity of the glycopeptides toward Gram-negative organisms.
Collapse
Affiliation(s)
- Emma van Groesen
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University 2333 BE Leiden, The Netherlands
| | - Paolo Innocenti
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University 2333 BE Leiden, The Netherlands
| | - Nathaniel I Martin
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University 2333 BE Leiden, The Netherlands
| |
Collapse
|
9
|
Flores-Holguín N, Frau J, Glossman-Mitnik D. Computational Chemistry Study of Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates as Therapeutic Drugs. Physiology (Bethesda) 2022. [DOI: 10.5772/intechopen.103130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The objective of the research to be presented in the chapter is the determination of the chemical reactivity properties of some natural apocarotenoids and their synthetic glycopeptide conjugates that could have the ability to inhibit SARS-CoV-2 replication. The study will be based on the consideration of the Conceptual DFT branch of Density Functional Theory (DFT) through the consideration of particular successful model chemistry which has been demonstrated as satisfying the Janak and Ionization Energy theorems within Generalized Gradient Approximation (GGA) theory. The research will be complemented by a report of the ADMET and pharmacokinetic properties hoping that this information could be of help in the development of new pharmaceutical drugs for fighting COVID-19.
Collapse
|
10
|
Acharya Y, Bhattacharyya S, Dhanda G, Haldar J. Emerging Roles of Glycopeptide Antibiotics: Moving beyond Gram-Positive Bacteria. ACS Infect Dis 2022; 8:1-28. [PMID: 34878254 DOI: 10.1021/acsinfecdis.1c00367] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Glycopeptides, a class of cell wall biosynthesis inhibitors, have been the antibiotics of choice against drug-resistant Gram-positive bacterial infections. Their unique mechanism of action involving binding to the substrate of cell wall biosynthesis and substantial longevity in clinics makes this class of antibiotics an attractive choice for drug repurposing and reprofiling. However, resistance to glycopeptides has been observed due to alterations in the substrate, cell wall thickening, or both. The emergence of glycopeptide resistance has resulted in the development of synthetic and semisynthetic glycopeptide analogues to target acquired resistance. Recent findings demonstrate that these derivatives, along with some of the FDA approved glycopeptides have been shown to have antimicrobial activity against Gram-negative bacteria, Mycobacteria, and viruses thus expanding their spectrum of activity across the microbial kingdom. Additional mechanisms of action and identification of novel targets have proven to be critical in broadening the spectrum of activity of glycopeptides. This review focuses on the applications of glycopeptides beyond their traditional target group of Gram-positive bacteria. This will aid in making the scientific community aware about the nontraditional activity profiles of glycopeptides, identify the existing loopholes, and further explore this antibiotic class as a potential broad-spectrum antimicrobial agent.
Collapse
Affiliation(s)
- Yash Acharya
- Antimicrobial Research Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur, Bengaluru 560064, Karnataka, India
| | - Shaown Bhattacharyya
- Biochemistry and Molecular Biology Program, Departments of Chemistry and Biology, College of Arts and Science, Boston University, Boston, Massachusetts 02215, United States
| | - Geetika Dhanda
- Antimicrobial Research Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur, Bengaluru 560064, Karnataka, India
| | - Jayanta Haldar
- Antimicrobial Research Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur, Bengaluru 560064, Karnataka, India
- School of Advanced Materials, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Jakkur, Bengaluru 560064, Karnataka, India
| |
Collapse
|
11
|
Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication. Pharmaceuticals (Basel) 2021; 14:ph14111111. [PMID: 34832893 PMCID: PMC8619593 DOI: 10.3390/ph14111111] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 10/26/2021] [Accepted: 10/26/2021] [Indexed: 12/24/2022] Open
Abstract
The protracted global COVID-19 pandemic urges the development of new drugs against the causative agent SARS-CoV-2. The clinically used glycopeptide antibiotic, teicoplanin, emerged as a potential antiviral, and its efficacy was improved with lipophilic modifications. This prompted us to prepare new lipophilic apocarotenoid conjugates of teicoplanin, its pseudoaglycone and the related ristocetin aglycone. Their antiviral effect was tested against SARS-CoV-2 in Vero E6 cells, using a cell viability assay and quantitative PCR of the viral RNA, confirming their micromolar inhibitory activity against viral replication. Interestingly, two of the parent apocarotenoids, bixin and β-apo-8′carotenoic acid, exerted remarkable anti-SARS-CoV-2 activity. Mechanistic studies involved cathepsin L and B, as well as the main protease 3CLPro, and the results were rationalized by computational studies. Glycopeptide conjugates show dual inhibitory action, while apocarotenoids have mostly cathepsin B and L affinity. Since teicoplanin is a marketed antibiotic and the natural bixin is an approved, cheap and widely used red colorant food additive, these readily available compounds and their conjugates as potential antivirals are worthy of further exploration.
Collapse
|
12
|
Demsie DG, Gebre AK, Yimer EM, Alema NM, Araya EM, Bantie AT, Allene MD, Gebremedhin H, Yehualaw A, Tafere C, Tadese HT, Amare B, Weldekidan E, Gebrie D. Glycopeptides as Potential Interventions for COVID-19. Biologics 2020; 14:107-114. [PMID: 33116397 PMCID: PMC7569252 DOI: 10.2147/btt.s262705] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 08/11/2020] [Indexed: 01/07/2023]
Abstract
Coronavirus disease 2019 (COVID-19), an infectious disease that primarily attacks the human pulmonary system, is caused by a viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The outbreak emerged from Wuhan, China, and later spread throughout the world. Until the first week of May 2020, over 3.7 million cases had been reported worldwide and more than 258,000 had died due to the disease. So far, off label use of various drugs has been tried in many clinical settings, however, at present, there is no vaccine or antiviral treatment for human and animal coronaviruses. Therefore, repurposing of the available drugs may be promising to control emerging infections of SARS-COV2; however, new interventions are likely to require months to years to develop. Glycopeptides, which are active against gram-positive bacteria, have demonstrated significant activity against viral infections including SARS-COV and MERS-COV and have a high resemblance of sequence homology with SARS-COV2. Recent in vitro studies have also shown promising activities of aglycon derivative of glycopeptides and teicoplanin against SARS-COV2. Hydrophobic aglycon derivatives and teicoplanin, with minimal toxicity to human cell lines, inhibit entry and replication of SARS-COV2. These drugs block proteolysis of polyprotein a/b with replicase and transcription domains. Teicoplanin use was associated with complete viral clearance in a cohort of patients with severe COVID-19 symptoms. This review attempts to describe the activity, elucidate the possible mechanisms and potential clinical applications of existing glycopeptides against corona viruses, specifically SARS-COV2.
Collapse
Affiliation(s)
- Desalegn Getnet Demsie
- Adigrat University, College of Medicine and Health Sciences, Department of Pharmacy, Adigrat, Ethiopia,Correspondence: Desalegn Getnet Demsie Email
| | - Abadi Kahsu Gebre
- Mekelle University, College of Health Sciences, Department of Pharmacology and Toxicology, Mekelle, Ethiopia
| | - Ebrahim M Yimer
- Wollo University, College of Medicine and Health Sciences, Department of Pharmacy, Dessie, Ethiopia
| | - Niguse Meles Alema
- Adigrat University, College of Medicine and Health Sciences, Department of Pharmacy, Adigrat, Ethiopia
| | - Ephrem Mebrahtu Araya
- Adigrat University, College of Medicine and Health Sciences, Department of Pharmacy, Adigrat, Ethiopia
| | - Abere Tilahun Bantie
- Adigrat University, College of Medicine and Health Sciences, Department of Anesthesia, Adigrat, Ethiopia
| | - Mengesha Dessie Allene
- Debre Berhan University, School of Medicine, College of Medicine, Department of Anesthesia, Debre Berhan, Ethiopia
| | - Hagazi Gebremedhin
- Mekelle University, College of Health Sciences, Department of Pharmacology and Toxicology, Mekelle, Ethiopia
| | - Adane Yehualaw
- Bahir Dar University, College of Health Sciences, Department of Pharmacy, Bahir Dar, Ethiopia
| | - Chernet Tafere
- Bahir Dar University, College of Health Sciences, Department of Pharmacy, Bahir Dar, Ethiopia
| | | | - Bekalu Amare
- Mekelle University, College of Health Sciences, Department of Pharmacology and Toxicology, Mekelle, Ethiopia
| | - Etsay Weldekidan
- Adigrat University, College of Medicine and Health Sciences, Department of Pharmacy, Adigrat, Ethiopia
| | - Desye Gebrie
- Mekelle University, College of Health Sciences, Department of Social Pharmacy and Pharmacoepidemiology, Mekelle, Ethiopia,Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa, Addis Ababa, Ethiopia
| |
Collapse
|
13
|
Kaddoura M, AlIbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, Haddad S, Eid A, Zaraket H. COVID-19 Therapeutic Options Under Investigation. Front Pharmacol 2020; 11:1196. [PMID: 32848795 PMCID: PMC7424051 DOI: 10.3389/fphar.2020.01196] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 07/22/2020] [Indexed: 12/15/2022] Open
Abstract
Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19-associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients.
Collapse
Affiliation(s)
- Malak Kaddoura
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Malak AlIbrahim
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Ghina Hijazi
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Nadia Soudani
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Amani Audi
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Habib Alkalamouni
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Salame Haddad
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Ali Eid
- Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Hassan Zaraket
- Department of Experimental Pathology, Immunology & Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
- Center for Infectious Disease Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| |
Collapse
|
14
|
Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity. Pharmaceuticals (Basel) 2020; 13:ph13070139. [PMID: 32610683 PMCID: PMC7407158 DOI: 10.3390/ph13070139] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 06/25/2020] [Accepted: 06/26/2020] [Indexed: 01/05/2023] Open
Abstract
Influenza A and B viruses are a global threat to human health and increasing resistance to the existing antiviral drugs necessitates new concepts to expand the therapeutic options. Glycopeptide derivatives have emerged as a promising new class of antiviral agents. To avoid potential antibiotic resistance, these antiviral glycopeptides are preferably devoid of antibiotic activity. We prepared six vancomycin aglycone hexapeptide derivatives with the aim of obtaining compounds having anti-influenza virus but no antibacterial activity. Two of them exerted strong and selective inhibition of influenza A and B virus replication, while antibacterial activity was successfully eliminated by removing the critical N-terminal moiety. In addition, these two molecules offered protection against several other viruses, such as herpes simplex virus, yellow fever virus, Zika virus, and human coronavirus, classifying these glycopeptides as broad antiviral molecules with a favorable therapeutic index.
Collapse
|
15
|
Kumar R, Gupta N, Kodan P, Mittal A, Soneja M, Wig N. Battling COVID-19: using old weapons for a new enemy. Trop Dis Travel Med Vaccines 2020; 6:6. [PMID: 32454984 PMCID: PMC7237624 DOI: 10.1186/s40794-020-00107-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Accepted: 05/08/2020] [Indexed: 12/18/2022] Open
Abstract
Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19.
Collapse
Affiliation(s)
- Rohit Kumar
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, 110029 India
| | - Nitin Gupta
- Department of Infectious Diseases, Kasturba Medical College, Manipal, Karnataka 576104 India
| | - Parul Kodan
- Dr Ram Manohar Lohia hospital & Post-Graduate Institute of Medica education and Research, New Delhi, 110001 India
| | - Ankit Mittal
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, 110029 India
| | - Manish Soneja
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, 110029 India
| | - Naveet Wig
- Department of Medicine, All India Institute of Medical Sciences, New Delhi, 110029 India
| |
Collapse
|
16
|
Szűcs Z, Kelemen V, Le Thai S, Csávás M, Rőth E, Batta G, Stevaert A, Vanderlinden E, Naesens L, Herczegh P, Borbás A. Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents. Eur J Med Chem 2018; 157:1017-1030. [PMID: 30170320 PMCID: PMC7115582 DOI: 10.1016/j.ejmech.2018.08.058] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 08/20/2018] [Accepted: 08/21/2018] [Indexed: 02/03/2023]
Abstract
Six series of semisynthetic lipophilic glycopeptide antibiotic derivatives were evaluated for in vitro activity against influenza A and B viruses. The new teicoplanin pseudoaglycon-derived lipoglycopeptides were prepared by coupling one or two side chains to the N-terminus of the glycopeptide core, using various conjugation methods. Three series of derivatives bearing two lipophilic groups were synthesized by attaching bis-alkylthio maleimides directly or through linkers of different lengths to the glycopeptide. Access to the fourth and fifth series of compounds was achieved by click chemistry, introducing single alkyl/aryl chains directly or through a tetraethylene glycol linker to the same position. A sixth group of semisynthetic derivatives was obtained by sulfonylation of the N-terminus. Of the 42 lipophilic teicoplanin pseudoaglycon derivatives tested, about half showed broad activity against influenza A and B viruses, with some of them having reasonable or no cytotoxicity. Minor differences in the side chain length as well as lipophilicity appeared to have significant impact on antiviral activity and cytotoxicity. Several lipoglycopeptides were also found to be active against human coronavirus. Multiple series of lipophilic teicoplanin pseudoaglycon derivatives were prepared. Alkyl or aryl chains were coupled to the N-terminus by various conjugation methods. The activity of new antibiotic derivatives was evaluated against influenza viruses. Half of the 42 derivatives showed high activity against influenza A and B viruses. The length and lipophilicity of the side chains influence the antiviral activity.
Collapse
Affiliation(s)
- Zsolt Szűcs
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Viktor Kelemen
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Son Le Thai
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Magdolna Csávás
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Erzsébet Rőth
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary
| | - Gyula Batta
- Department of Organic Chemistry, University of Debrecen, H-4032 Debrecen, Hungary
| | - Annelies Stevaert
- Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium
| | | | - Lieve Naesens
- Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium.
| | - Pál Herczegh
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.
| | - Anikó Borbás
- Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.
| |
Collapse
|
17
|
Amarasekara H, Dharuman S, Kato T, Crich D. Synthesis of Conformationally-Locked cis- and trans-Bicyclo[4.4.0] Mono-, Di-, and Trioxadecane Modifications of Galacto- and Glucopyranose; Experimental Limiting 3J H,H Coupling Constants for the Estimation of Carbohydrate Side Chain Populations and Beyond. J Org Chem 2018; 83:881-897. [PMID: 29241001 PMCID: PMC5775050 DOI: 10.1021/acs.joc.7b02891] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Hexopyranose side chains populate three staggered conformations, whose proportions can be determined from the three sets of ideal limiting 3JH5,H6R and 3JH5,H6S coupling constants in combination with the time-averaged experimental coupling constants. Literature values for the limiting coupling constants, obtained by the study of model compounds, the use of the Haasnoot-Altona and related equations, or quantum mechanical computations, can result in computed negative populations of one of the three ideal conformations. Such values arise from errors in the limiting coupling constants and/or from the population of nonideal conformers. We describe the synthesis and analysis of a series of cis- and trans-fused mono-, di-, and trioxabicyclo[4.4.0]octane-like compounds. Correction factors for the application of data from internal models (-CH(OR)-CH(OR)-) to terminal systems (-CH(OR)-CH2(OR)) are deduced from comparison of further models, and applied where necessary. Limiting coupling constants so-derived are applied to the side chain conformations of three model hexopyranosides, resulting in calculated conformer populations without negative values. Although, developed primarily for hexopyranose side chains, the limiting coupling constants are suitable, with the correction factors presented, for application to the side chains of higher carbon sugars and to conformation analysis of acyclic diols and their derivatives in a more general sense.
Collapse
Affiliation(s)
- Harsha Amarasekara
- Department of Chemistry, Wayne State University , Detroit, Michigan 48202, United States
| | - Suresh Dharuman
- Department of Chemistry, Wayne State University , Detroit, Michigan 48202, United States
| | - Takayuki Kato
- Department of Chemistry, Wayne State University , Detroit, Michigan 48202, United States
| | - David Crich
- Department of Chemistry, Wayne State University , Detroit, Michigan 48202, United States
| |
Collapse
|
18
|
Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci. J Antibiot (Tokyo) 2017; 70:664-670. [PMID: 28144040 DOI: 10.1038/ja.2017.2] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Revised: 12/06/2016] [Accepted: 12/18/2016] [Indexed: 12/18/2022]
Abstract
A selection of nine derivatives of teicoplanin pseudoaglycon were tested in vitro against clinical vancomycin-resistant Enterococcus strains possessing vanA, vanB or both genes. The bacteria were characterized by PCR for the identification of their resistance genes. The tested compounds contain lipoic acid, different carbohydrates and aryl groups as lipophilic moieties. About one-third of the teicoplanin-resistant strains were shown to be susceptible to one or more of the glycopeptide derivatives.
Collapse
|
19
|
Colson P, Raoult D. Fighting viruses with antibiotics: an overlooked path. Int J Antimicrob Agents 2016; 48:349-52. [PMID: 27546219 PMCID: PMC7134768 DOI: 10.1016/j.ijantimicag.2016.07.004] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 07/02/2016] [Indexed: 01/07/2023]
Affiliation(s)
- Philippe Colson
- Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalo-Universitaire Timone, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Marseille, France; Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63 CNRS 7278 IRD 198 INSERM U1095, Marseille, France
| | - Didier Raoult
- Institut Hospitalo-Universitaire (IHU) Méditerranée Infection, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalo-Universitaire Timone, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Marseille, France; Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63 CNRS 7278 IRD 198 INSERM U1095, Marseille, France.
| |
Collapse
|
20
|
Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem 2016; 291:9218-32. [PMID: 26953343 PMCID: PMC4861487 DOI: 10.1074/jbc.m116.716100] [Citation(s) in RCA: 196] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Indexed: 01/18/2023] Open
Abstract
Ebola virus infection can cause severe hemorrhagic fever with a high mortality in
humans. The outbreaks of Ebola viruses in 2014 represented the most serious
Ebola epidemics in history and greatly threatened public health worldwide. The
development of additional effective anti-Ebola therapeutic agents is therefore
quite urgent. In this study, via high throughput screening of Food and Drug
Administration-approved drugs, we identified that teicoplanin, a glycopeptide
antibiotic, potently prevents the entry of Ebola envelope pseudotyped viruses
into the cytoplasm. Furthermore, teicoplanin also has an inhibitory effect on
transcription- and replication-competent virus-like particles, with an
IC50 as low as 330 nm. Comparative analysis further
demonstrated that teicoplanin is able to block the entry of Middle East
respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS)
envelope pseudotyped viruses as well. Teicoplanin derivatives such as
dalbavancin, oritavancin, and telavancin can also inhibit the entry of Ebola,
MERS, and SARS viruses. Mechanistic studies showed that teicoplanin blocks Ebola
virus entry by specifically inhibiting the activity of cathepsin L, opening a
novel avenue for the development of additional glycopeptides as potential
inhibitors of cathepsin L-dependent viruses. Notably, given that teicoplanin has
routinely been used in the clinic with low toxicity, our work provides a
promising prospect for the prophylaxis and treatment of Ebola, MERS, and SARS
virus infection.
Collapse
Affiliation(s)
- Nan Zhou
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Ting Pan
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Junsong Zhang
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Qianwen Li
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Xue Zhang
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Chuan Bai
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Feng Huang
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Tao Peng
- the Sino-French Hoffmann Institute, Guangzhou Medical University, Guangzhou 510182, Guangdong, and
| | - Jianhua Zhang
- the CAS Key Laboratory for Pathogenic Microbiology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
| | - Chao Liu
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong
| | - Liang Tao
- Department of Pharmacology, Zhongshan School of Medicine
| | - Hui Zhang
- From the Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, and Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Sun Yat-sen University, Guangzhou 510080, Guangdong,
| |
Collapse
|
21
|
Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, Zou G. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res 2015; 125:1-7. [PMID: 26585243 PMCID: PMC7113690 DOI: 10.1016/j.antiviral.2015.11.003] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 11/05/2015] [Accepted: 11/09/2015] [Indexed: 11/16/2022]
Abstract
There is currently no approved antiviral therapy for treatment of Ebola virus disease. To discover readily available approved drugs that can be rapidly repurposed for treatment of Ebola virus infections, we screened 1280 FDA-approved drugs and identified glycopeptide antibiotic teicoplanin inhibiting Ebola pseudovirus infection by blocking virus entry in the low micromolar range. Teicoplanin could be evaluated further and incorporated into ongoing clinical studies.
Collapse
Affiliation(s)
- Yizhuo Wang
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
| | - Rui Cui
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Sciences, Shanghai University, Shanghai 200444, China
| | - Guiming Li
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China; School of Life Sciences, Shanghai University, Shanghai 200444, China
| | - Qianqian Gao
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
| | - Shilin Yuan
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
| | - Ralf Altmeyer
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
| | - Gang Zou
- Unit of Anti-infective Research, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
| |
Collapse
|
22
|
Chen M, Hu D, Li X, Yang S, Zhang W, Li P, Song B. Antiviral activity and interaction mechanisms study of novel glucopyranoside derivatives. Bioorg Med Chem Lett 2015; 25:3840-4. [DOI: 10.1016/j.bmcl.2015.07.068] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 07/19/2015] [Accepted: 07/21/2015] [Indexed: 12/01/2022]
|
23
|
Csávás M, Miskovics A, Szűcs Z, Rőth E, Nagy ZL, Bereczki I, Herczeg M, Batta G, Nemes-Nikodém É, Ostorházi E, Rozgonyi F, Borbás A, Herczegh P. Synthesis and antibacterial evaluation of some teicoplanin pseudoaglycon derivatives containing alkyl- and arylthiosubstituted maleimides. J Antibiot (Tokyo) 2015; 68:579-85. [PMID: 25829202 DOI: 10.1038/ja.2015.33] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Revised: 02/18/2015] [Accepted: 02/27/2015] [Indexed: 12/11/2022]
Abstract
Bis-alkylthio maleimido derivatives have been prepared from teicoplanin pseudoaglycon by reaction of its primary amino group with N-ethoxycarbonyl bis-alkylthiomaleimides. Some of the new derivatives displayed excellent antibacterial activity against resistant bacteria.
Collapse
Affiliation(s)
- Magdolna Csávás
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Adrienn Miskovics
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Zsolt Szűcs
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Erzsébet Rőth
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Zsolt L Nagy
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Ilona Bereczki
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Mihály Herczeg
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Gyula Batta
- Department of Organic Chemistry, University of Debrecen, Debrecen, Hungary
| | - Éva Nemes-Nikodém
- Department of Dermatology, Venerology and Dermatooncology, Microbiology Laboratory, Semmelweis University, Budapest, Hungary
| | - Eszter Ostorházi
- Department of Dermatology, Venerology and Dermatooncology, Microbiology Laboratory, Semmelweis University, Budapest, Hungary
| | - Ferenc Rozgonyi
- Department of Dermatology, Venerology and Dermatooncology, Microbiology Laboratory, Semmelweis University, Budapest, Hungary
| | - Anikó Borbás
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| | - Pál Herczegh
- Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Hungary
| |
Collapse
|